Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Asset Writedowns and Impairment (2019 - 2022)

Standard Biotools (LAB) reported Asset Writedowns and Impairment of $3.5 million for Q2 2022, up 775.0% on a QoQ basis from $400000.0 in Q4 2019.

Standard Biotools (LAB) has 2 years of Asset Writedowns and Impairment data on file, last reported at $3.5 million in Q2 2022.

  • Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $3.5 million in Q2 2022, while the trailing twelve-month figure through Dec 2023 was $3.5 million (changed 0.0% YoY) and the FY2022 annual result came in at $3.5 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment climbed to $3.5 million in Q2 2022 per LAB's latest filing, from $400000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $3.5 million in Q2 2022 and bottomed at $400000.0 in Q4 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Standard Biotools 448.37 Mn -6.80 Mn 11.31 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2022 3.50 Mn
Jun 30, 2022 3.50 Mn
Dec 31, 2019 400,000.00
Dec 31, 2019 400,000.00